LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

CareDx Inc

Cerrado

SectorSalud

19.11 -2.9

Resumen

Variación precio

24h

Actual

Mínimo

18.77

Máximo

20.08

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.773

121.746

Margen de beneficio

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

-10.85% downside

Dividendos

By Dow Jones

Próximas Ganancias

24 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

288M

1.1B

Apertura anterior

22.01

Cierre anterior

19.11

Noticias sobre sentimiento de mercado

By Acuity

11%

89%

9 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 feb 2026, 23:57 UTC

Acciones populares

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 feb 2026, 23:35 UTC

Ganancias
Principales Movimientos del Mercado

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 feb 2026, 23:28 UTC

Ganancias

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 feb 2026, 21:47 UTC

Ganancias

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 feb 2026, 00:00 UTC

Charlas de Mercado

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 feb 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 feb 2026, 23:38 UTC

Charlas de Mercado

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 feb 2026, 23:33 UTC

Ganancias

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 feb 2026, 23:09 UTC

Charlas de Mercado

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 feb 2026, 22:55 UTC

Ganancias
Acciones populares

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 feb 2026, 22:46 UTC

Charlas de Mercado

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 feb 2026, 22:23 UTC

Ganancias

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 feb 2026, 22:15 UTC

Ganancias

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 feb 2026, 22:15 UTC

Ganancias

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 feb 2026, 22:15 UTC

Ganancias

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 feb 2026, 22:15 UTC

Ganancias

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 feb 2026, 22:00 UTC

Ganancias

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb 2026, 22:00 UTC

Ganancias

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 feb 2026, 22:00 UTC

Ganancias

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 feb 2026, 22:00 UTC

Ganancias

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 feb 2026, 22:00 UTC

Ganancias

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb 2026, 22:00 UTC

Ganancias

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 feb 2026, 21:57 UTC

Ganancias

XP 4Q Rev BRL4.95B >XP

12 feb 2026, 21:52 UTC

Ganancias

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

12 feb 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

12 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 feb 2026, 21:47 UTC

Ganancias

Morningstar 4Q Rev $641M >MORN

12 feb 2026, 21:39 UTC

Ganancias

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb 2026, 21:38 UTC

Ganancias

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Comparación entre iguales

Cambio de precio

CareDx Inc Esperado

Precio Objetivo

By TipRanks

-10.85% caída

Estimación a 12 meses

Media 18 USD  -10.85%

Máximo 18 USD

Mínimo 18 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

0

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

9 / 352 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat